The U.S. Food and Drug Administration has added a warning about kidney injury to the labeling of a popular over-the-counter weight-loss pill. According to drug-safety reporting, the update applies to the nonprescription weight-loss product orlistat, sold under a well-known brand, and flags the risk of kidney stones and kidney injury.
Over-the-counter status can create a false sense of safety, as if a product available without a prescription must be free of serious risks. Label updates like this one are a reminder that nonprescription drugs still carry meaningful side effects, and that the absence of a doctor’s gatekeeping makes clear warnings all the more important.
What changed on the label
The FDA’s labeling update adds explicit language about the potential for kidney stones and kidney injury among users. Label changes like this reflect accumulated reports and safety reviews, and they are meant to ensure consumers and clinicians are aware of risks that may not have been prominent when a product first reached the market.
Regulators revisit labeling as real-world data accumulate, and a new warning typically signals that reports of a particular harm have reached a threshold worth flagging. For a product bought off the shelf and used without medical supervision, spelling out the kidney risk on the label is often the main way that information reaches the people taking it.
How the drug works
Orlistat reduces the amount of dietary fat the body absorbs by blocking an enzyme in the gut. Because it is available without a prescription, many people take it without medical oversight, which makes clear labeling especially important. The kidney-related warning gives users a concrete reason to be attentive to symptoms and to hydration.
By preventing the absorption of some dietary fat, orlistat can aid weight loss but also produces gastrointestinal side effects, and the newly emphasized kidney risk adds another consideration. Because no clinician is necessarily monitoring an over-the-counter user, the burden of watching for warning signs falls more heavily on the individual, underscoring the value of clear label information.
What consumers should watch for
Anyone taking an over-the-counter weight-loss aid should read the updated labeling and be alert to signs of kidney trouble, such as changes in urination, back or side pain, or blood in the urine. People with existing kidney conditions or a history of kidney stones should be especially cautious and may want to consult a clinician before use. The broader reminder is that over-the-counter status does not mean a product is free of meaningful risks.
Staying well hydrated and being attentive to symptoms can help reduce or catch kidney problems early. Those with prior kidney issues have particular reason to check with a healthcare provider before starting the drug, since they may face elevated risk. The label change is ultimately a prompt for informed, cautious use rather than a reason for panic — but it is a prompt worth heeding.
This article was researched with the help of AI, with human editors creating the final content.
